全身性強皮症– category –

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial Dinesh Khanna, Celia J F Lin, Daniel E Furst, Jonathan Goldi...

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-b...

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, para...

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, ...

Cyclophosphamide versus Placebo in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel ...

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial Dinesh Khanna, Celia J F Lin, Daniel E Furst, Jonathan Goldi...

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, para...

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-b...

Cyclophosphamide versus Placebo in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel ...

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, ...